Emerson Electric Co.

EMRNYSEUSD

THESIS ALERT

Email me when the EMR thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$167.06
−$0.48 (−0.29%)Today 1M +3.53%
After hours$167.10+0.02%

Updated Nov 11, 4:03 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$167.54
Prior regular-session close from the quote source.
$166.97–$169.75
Regular-session low and high so far today.
1.9M
Regular-session shares traded · Nov 11, 4:03 PM ET.
Not yet confirmed
The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
$122.64–$172.00
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own EMR if Emerson turns industrial technology and embedded software plus an installed base and aftermarket into durable, cash-generative revenue; margin improvement and disciplined capital allocation convert that cash into steady EPS growth.

EMR price history

Latest price$167.06Today−$0.48 (-0.29%)
EMR +2.57%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • A growing share of Emerson’s revenue is driven by software, services and aftermarket attached to an installed base, making overall revenue less cyclical and more predictable.HoldingMateriality: High

    Revenue increased from 13,804,000,000 (FY2022) to 18,016,000,000 (FY2025), showing multi-year top-line expansion. If true, revenue becomes steadier and more defensible, supporting higher margins, better cash conversion and a higher multiple; if false, revenue will remain capex‑cyclical and volatile.

    Watch: A sustained decline in industrial capex across Emerson’s end markets that reduces product attach and aftermarket spend.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Revenue increased from 13,804,000,000 (FY2022) to 18,016,000,000 (FY2025), showing multi-year top-line expansion.

    Open source ↗
  • Improvements in product mix, pricing and cost control (reflected in rising gross profit) will sustain higher gross and operating margins, protecting cash generation as revenue grows.StrengtheningMateriality: High

    Gross profit rose from 6,306,000,000 (FY2022) to 9,519,000,000 (FY2025), indicating improved mix or pricing and/or cost control. Sustained margin expansion converts revenue into operating income and cash; without it, revenue growth has less impact on EPS and enterprise value.

    Watch: Raw-material or component cost shocks or renewed supply-chain stress that compresses margins.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Gross profit rose from 6,306,000,000 (FY2022) to 9,519,000,000 (FY2025), indicating improved mix or pricing and/or cost control.

    Open source ↗
  • Emerson’s ability to convert operating profits into operating cash flow at scale will fund dividends/buybacks and drive EPS even if organic revenue growth is moderate.StrengtheningMateriality: Medium

    Operating cash flow increased from 637,000,000 (FY2023) to 3,098,000,000 (FY2025), showing much stronger cash generation. High cash conversion allows management to return cash to shareholders and support per-share EPS growth without relying solely on high top-line growth.

    Watch: Large, recurring negative working-capital swings or materially higher capex that reduce free cash flow despite operating profits.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Operating cash flow increased from 637,000,000 (FY2023) to 3,098,000,000 (FY2025), showing much stronger cash generation.

    Open source ↗
  • Reported net income is materially affected by non-recurring items (asset sales, tax items, restructuring), so sustainable earnings must be judged by operating cash flow and recurring operating results rather than headline net_income.StrengtheningMateriality: Medium

    Net income shows a large spike to 13,219,000,000 (FY2023) versus 1,968,000,000 (FY2024) and 2,293,000,000 (FY2025), implying major one-time items in FY2023. If headline net income is driven by one-offs, investors who rely on it will misread underlying performance; consistent FCF and operating metrics are the right gauges.

    Watch: Recurring large asset sales or frequent sizable tax/other non-operating gains that keep headline net income lumpy.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Net income shows a large spike to 13,219,000,000 (FY2023) versus 1,968,000,000 (FY2024) and 2,293,000,000 (FY2025), implying major one-time items in.

    Open source ↗
  • The material decline in reported cash balances indicates aggressive capital deployment (buybacks, dividends, acquisitions) — this can accelerate EPS if returns exceed cost of capital but risks balance-sheet strain if operating cash flow weakens.HoldingMateriality: Medium

    Cash fell from 8,051,000,000 (FY2023) to 1,544,000,000 (FY2025), a material decrease that signals significant deployment. If cash is being spent wisely, EPS and ROE rise; if spent on poor M&A or sustained while cash flow weakens, financial flexibility and credit metrics worsen.

    Watch: Unexpected large acquisitions that do not generate accretive cash returns.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash fell from 8,051,000,000 (FY2023) to 1,544,000,000 (FY2025), a material decrease that signals significant deployment.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

A growing share of Emerson’s revenue is driven by software, services and aftermarket attached to an installed base, making overall revenue less cyclical and more predictable. If true, revenue becomes steadier and more defensible, supporting higher margins, better cash conversion and a higher multiple; if false, revenue will remain capex‑cyclical and volatile.

Improvements in product mix, pricing and cost control (reflected in rising gross profit) will sustain higher gross and operating margins, protecting cash generation as revenue grows. Sustained margin expansion converts revenue into operating income and cash; without it, revenue growth has less impact on EPS and enterprise value.

Emerson’s ability to convert operating profits into operating cash flow at scale will fund dividends/buybacks and drive EPS even if organic revenue growth is moderate. High cash conversion allows management to return cash to shareholders and support per-share EPS growth without relying solely on high top-line growth.

Reported net income is materially affected by non-recurring items (asset sales, tax items, restructuring), so sustainable earnings must be judged by operating cash flow and recurring operating results rather than headline net_income. If headline net income is driven by one-offs, investors who rely on it will misread underlying performance; consistent FCF and operating metrics are the right gauges.

The material decline in reported cash balances indicates aggressive capital deployment (buybacks, dividends, acquisitions) — this can accelerate EPS if returns exceed cost of capital but risks balance-sheet strain if operating cash flow weakens. If cash is being spent wisely, EPS and ROE rise; if spent on poor M&A or sustained while cash flow weakens, financial flexibility and credit metrics worsen.

All standing thesis claims
Original report summary

Emerson turns industrial technology and embedded software plus an installed base and aftermarket into durable, cash-generative revenue; margin improvement and disciplined capital allocation convert that cash into steady EPS growth.

Evidence assessed Oct 16, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Emerson Electric Co

Where the evidence on Emerson Electric Co stands: Holding on the latest evidence (Oct 16, 2026). Of its 5 thesis points, 3 strengthening and 2 holding.

Bull case: what the evidence supports

  • A growing share of Emerson’s revenue is driven by software, services and aftermarket attached to an installed base, making overall revenue less cyclical and more predictable.

    sec.gov ↗

  • Improvements in product mix, pricing and cost control (reflected in rising gross profit) will sustain higher gross and operating margins, protecting cash generation as revenue grows.

    sec.gov ↗

  • Emerson’s ability to convert operating profits into operating cash flow at scale will fund dividends/buybacks and drive EPS even if organic revenue growth is moderate.

    sec.gov ↗

  • Reported net income is materially affected by non-recurring items (asset sales, tax items, restructuring), so sustainable earnings must be judged by operating cash flow and recurring operating results rather than headline net_income.

    sec.gov ↗

  • The material decline in reported cash balances indicates aggressive capital deployment (buybacks, dividends, acquisitions) — this can accelerate EPS if returns exceed cost of capital but risks balance-sheet strain if operating cash flow weakens.

    sec.gov ↗

Bear case: what would count against it

  • A sustained decline in industrial capex across Emerson’s end markets that reduces product attach and aftermarket spend.

    sec.gov ↗

  • Raw-material or component cost shocks or renewed supply-chain stress that compresses margins.

    sec.gov ↗

  • Large, recurring negative working-capital swings or materially higher capex that reduce free cash flow despite operating profits.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Emerson Electric Co

Loading the break-condition record for Emerson Electric Co.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    Emerson Electric Co filed an SEC 8-K on 2026-10-13: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Reported results of operations (earnings release).

    Emerson Electric Co filed an SEC 8-K on 2026-08-04: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  3. Mixed
    Reported results of operations (earnings release).

    Emerson Electric Co filed an SEC 8-K on 2026-05-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • A sustained decline in industrial capex across Emerson’s end markets that reduces product attach and aftermarket spend.
  • Raw-material or component cost shocks or renewed supply-chain stress that compresses margins.
  • Large, recurring negative working-capital swings or materially higher capex that reduce free cash flow despite operating profits.
  • Recurring large asset sales or frequent sizable tax/other non-operating gains that keep headline net income lumpy.
  • Unexpected large acquisitions that do not generate accretive cash returns.

EMR news

Loading headlines…

Financial statements

EMR income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

EMR: quick answers

Have members of Congress traded EMR?
Reports made public in the last 90 days disclose 6 trades in EMR by 4 filers: 2 purchases and 4 sales. They are filed under the STOCK Act by members of Congress, the President and senior officials. Every disclosed EMR trade
Which well-known investors own EMR?
1 of the 37 well-known funds tracked here reported EMR shares in their latest 13F filing. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios

EMR in well-known investors’ portfolios

1 of 37 funds reported EMR shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.

FundOf its portfolioValueChangeQuarter
Ray DalioBridgewater Associates0.02%$5.2M−72.7%Q2 2026

Every fund’s portfolio

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.